Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (CRAD001NUS175T)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2016 by Dana-Farber Cancer Institute
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Lewis B. Silverman, M.D., Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01523977
First received: January 30, 2012
Last updated: February 12, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2018
  Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)